Pharmaceutical Preparations Industry - SEC Form 4 Insider Trading Screener
Manufacturing Sector - Chemicals - Pharmaceutical Preparations
100 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Share Price |
Shares Traded |
Shares Owned |
Own chg |
Value Traded |
1d ret |
1w ret |
1m ret |
6m ret |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2017-09-15 | PETX | Aratana Therapeutics, Inc. | Heinen Ernst | Chief Development Officer | S - Sale | $6.25 | -10,000 | 130,994 | -7% | -$62,500 | ||||||
2017-09-19 | ATHX | Athersys, Inc / New | Lehmann William Jr | Pres, COO | S - Sale | $2.38 | -15,000 | 512,380 | -3% | -$35,726 | ||||||
| M | 2017-09-15 | ATHX | Athersys, Inc / New | Harrington John J | Exec Vice Pres, CSO | S - Sale | $2.17 | -15,000 | 665,974 | -2% | -$32,508 | |||||
2017-09-18 | AMAR | Amarillo Biosciences Inc | Chen Stephen T | Pres, CEO, COB, 10% | P - Purchase | $0.28 | +3,000 | 3,865,696 | 0% | +$835 | ||||||
| D | 2017-09-18 | DERM | Dermira, Inc. | Wiggans Thomas G | CEO, COB | S - Sale+OE | $27.51 | -9,500 | 144,607 | -6% | -$261,336 | |||||
| D | 2017-09-15 | BMRN | Biomarin Pharmaceutical Inc | Lawlis V Bryan | Dir | S - Sale+OE | $91.26 | -3,750 | 15,910 | -19% | -$342,225 | |||||
| D | 2017-09-15 | BMRN | Biomarin Pharmaceutical Inc | Fuchs Henry J | Pres, Worldwide R, D | S - Sale+OE | $90.50 | -15,000 | 136,422 | -10% | -$1,357,500 | |||||
| M | 2017-09-14 | ENDV | Endonovo Therapeutics, Inc. | Mann Michael Scott | Pres, 10% | P - Purchase | $0.03 | +35,000 | 23,486,189 | 0% | +$915 | |||||
2017-09-18 | SNNA | Sienna Biopharmaceuticals, Inc. | Fenton Dennis M | Dir | P - Purchase | $22.96 | +1,250 | 1,250 | New | +$28,698 | ||||||
2017-09-18 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $6.00 | +40,000 | 187,774,456 | 0% | +$240,000 | ||||||
2017-09-18 | NBRV | Nabriva Therapeutics Plc | Vivo Capital Viii, LLC | 10% | P - Purchase | $9.46 | +52,631 | 4,074,190 | +1% | +$497,889 | ||||||
| M | 2017-03-29 | AGN | Allergan Plc | Saunders Brent L | COB, Pres, CEO | P - Purchase | $239.04 | +86 | 131,178 | 0% | +$20,626 | |||||
2017-09-15 | MRTX | Mirati Therapeutics, Inc. | Christensen Jamie | SVP, Chief Science Officer | S - Sale | $12.00 | -770 | 2,670 | -22% | -$9,240 | ||||||
| AM | 2017-09-13 | KALV | Kalvista Pharmaceuticals, Inc. | Novo Holdings A/s | 10% | S - Sale | $7.21 | -176,644 | 2,725,283 | -6% | -$1,273,956 | |||||
2017-09-18 | GLYC | Glycomimetics Inc | Thackray Helen M. | SVP Clinical Development, CMO | S - Sale | $13.00 | -2,000 | 150,615 | -1% | -$26,000 | ||||||
2017-09-15 | LFVN | Lifevantage Corp | Lewis Darwin | Dir | P - Purchase | $4.29 | +3,500 | 3,500 | New | +$15,015 | ||||||
2017-09-15 | LFVN | Lifevantage Corp | Mauro Garry Paul | Dir | P - Purchase | $4.20 | +3,500 | 58,640 | +6% | +$14,700 | ||||||
| D | 2017-09-14 | CNCE | Concert Pharmaceuticals, Inc. | Lynch Ryan | PFO, PAO | S - Sale+OE | $14.51 | -3,500 | 6,000 | -37% | -$50,785 | |||||
2017-09-15 | CLVS | Clovis Oncology, Inc. | Ivers-Read Gillian C | See Remarks | S - Sale | $69.50 | -3,000 | 191,583 | -2% | -$208,500 | ||||||
2017-09-18 | EPZM | Epizyme, Inc. | Mott David M | Dir | P - Purchase | $15.25 | +200,000 | 6,467,502 | +3% | +$3,050,000 | ||||||
| D | 2017-09-15 | KPTI | Karyopharm Therapeutics Inc. | Mirza Mansoor Raza | Dir | S - Sale+OE | $11.00 | -2,882 | 0 | -100% | -$31,702 | |||||
2017-09-15 | KPTI | Karyopharm Therapeutics Inc. | Primiano Christopher Brett | SVP, OPS, BUS DEV, GC, SEC | S - Sale | $11.00 | -2,000 | 12,881 | -13% | -$22,000 | ||||||
2017-09-15 | LLY | Lilly Eli & Co | Lilly Endowment Inc | 10% | S - Sale | $82.53 | -190,000 | 123,675,804 | 0% | -$15,679,772 | ||||||
2017-09-13 | IMGN | Immunogen Inc | Berkenblit Anna | VP, Chief Medical Officer | S - Sale | $7.00 | -1,500 | 161,800 | -1% | -$10,500 | ||||||
2017-09-15 | LXRX | Lexicon Pharmaceuticals, Inc. | Coats Lonnel | Pres, CEO | P - Purchase | $12.54 | +30,000 | 32,985 | >999% | +$376,337 | ||||||
2017-09-15 | LXRX | Lexicon Pharmaceuticals, Inc. | Barker Sam L | Dir | P - Purchase | $12.50 | +1,000 | 25,623 | +4% | +$12,500 | ||||||
2017-09-15 | OPK | Opko Health, Inc. | Logal Adam | SVP, CFO | P - Purchase | $6.03 | +1,500 | 162,793 | +1% | +$9,045 | ||||||
2017-09-15 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $6.01 | +80,000 | 187,734,456 | 0% | +$480,411 | ||||||
| DM | 2017-09-13 | PAHC | Phibro Animal Health Corp | Johnson Richard G | CFO | S - Sale+OE | $36.30 | -55,529 | 0 | -100% | -$2,015,473 | |||||
| DM | 2017-09-13 | PAHC | Phibro Animal Health Corp | Miller Larry Lee | COO | S - Sale+OE | $36.43 | -21,439 | 0 | -100% | -$781,000 | |||||
| M | 2017-09-13 | KALV | Kalvista Pharmaceuticals, Inc. | Novo Holdings A/s | 10% | S - Sale | $7.21 | -176,647 | 2,725,280 | -6% | -$1,273,980 | |||||
2017-09-14 | FGEN | Fibrogen Inc | Yu K Peony | Chief Medical Officer | S - Sale | $51.00 | -2,851 | 185,546 | -2% | -$145,401 | ||||||
2017-09-13 | FGEN | Fibrogen Inc | Riggs Rory B | Dir | S - Sale | $51.92 | -25,000 | 1,040,913 | -2% | -$1,298,000 | ||||||
| M | 2017-09-13 | FGEN | Fibrogen Inc | Neff Thomas B | CEO | S - Sale | $51.67 | -38,636 | 3,479,067 | -1% | -$1,996,274 | |||||
| DM | 2017-08-31 | FLXN | Flexion Therapeutics Inc | Deniz Yamo | Chief Medical Officer | P - Purchase | $24.48 | +5,375 | 9,000 | +148% | +$131,575 | |||||
| M | 2017-09-13 | CLSD | Clearside Biomedical, Inc. | Thorp Clay | Dir, 10% | S - Sale | $7.52 | -24,500 | 3,871,394 | -1% | -$184,185 | |||||
2017-09-13 | LOXO | Loxo Oncology, Inc. | Naider Avi Z. | Dir | S - Sale | $90.00 | -5,000 | 154,118 | -3% | -$450,000 | ||||||
| M | 2017-09-13 | AGIO | Agios Pharmaceuticals Inc | Cantley Lewis Clayton Jr. | Dir | S - Sale | $65.59 | -4,000 | 212,434 | -2% | -$262,360 | |||||
| DM | 2017-09-14 | MACK | Merrimack Pharmaceuticals Inc | Nielsen Ulrik B. | Dir | S - Sale+OE | $14.23 | -7,896 | 22,681 | -26% | -$112,357 | |||||
2017-09-14 | VTL | Vital Therapies Inc | Hasnain Faheem | Dir | P - Purchase | $4.19 | +59,200 | 185,443 | +47% | +$247,870 | ||||||
2017-09-11 | MTNB | Matinas Biopharma Holdings, Inc. | Mannino Raphael J | Chief Scientific Officer | P - Purchase | $1.41 | +5,000 | 1,424,565 | 0% | +$7,050 | ||||||
| DM | 2017-09-12 | AVDL | Avadel Pharmaceuticals Plc | Hatten Sandra L | See Remarks | P - Purchase | $9.25 | +6,000 | 41,200 | +17% | +$55,525 | |||||
| D | 2017-09-14 | UTHR | United Therapeutics Corp | Rothblatt Martine A | COB, CEO | S - Sale+OE | $122.08 | -1,258 | 674,487 | 0% | -$153,575 | |||||
| DM | 2017-09-13 | IMGN | Immunogen Inc | Barrows Craig | EVP, GC | S - Sale+OE | $6.81 | -37,050 | 44,050 | -46% | -$252,457 | |||||
| M | 2017-09-13 | RDUS | Radius Health, Inc. | Biotech Growth N V | 10% | P - Purchase | $33.45 | +150,000 | 5,498,799 | +3% | +$5,017,975 | |||||
| M | 2017-09-13 | KMPH | Kempharm, Inc | Delaware Street Capital Master Fund, L.P. | 10% | P - Purchase | $3.27 | +325,888 | 1,791,631 | +22% | +$1,066,827 | |||||
2017-09-14 | RDUS | Radius Health, Inc. | Carmona Jose | CFO | P - Purchase | $32.83 | +3,000 | 3,000 | New | +$98,503 | ||||||
2017-09-15 | RDUS | Radius Health, Inc. | Hoiland Jesper | Pres, CEO | P - Purchase | $32.72 | +6,100 | 6,100 | New | +$199,608 | ||||||
2017-09-14 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $5.98 | +260,000 | 187,654,456 | 0% | +$1,555,624 | ||||||
2017-09-13 | ADRO | Aduro Biotech, Inc. | Isaacs Stephen T | Pres, CEO | S - Sale | $10.99 | -12,204 | 244,578 | -5% | -$134,071 | ||||||
2017-09-13 | ADRO | Aduro Biotech, Inc. | Schafer Gregory W | COO | S - Sale | $10.99 | -4,859 | 148,745 | -3% | -$53,380 | ||||||
2017-09-13 | ADRO | Aduro Biotech, Inc. | Brockstedt Dirk G. | EVP of Research, Dev. | S - Sale | $10.99 | -3,557 | 73,718 | -5% | -$39,076 | ||||||
2017-09-13 | ADRO | Aduro Biotech, Inc. | Lew Jennifer | SVP of Finance | S - Sale | $10.99 | -3,557 | 62,338 | -5% | -$39,076 | ||||||
2017-09-13 | ADRO | Aduro Biotech, Inc. | Van Elsas Andrea | Chief Scientific Officer | S - Sale | $10.99 | -4,922 | 207,231 | -2% | -$54,072 | ||||||
2017-09-13 | ADRO | Aduro Biotech, Inc. | Templeman Blaine | EVP, GC | S - Sale | $10.99 | -3,557 | 61,718 | -5% | -$39,076 | ||||||
| M | 2017-09-12 | NBRV | Nabriva Therapeutics Plc | Hbm Healthcare Investments (Cayman) Ltd. | 10% | S - Sale | $8.56 | -36,608 | 2,334,128 | -2% | -$313,415 | |||||
| M | 2017-09-12 | VTL | Vital Therapies Inc | Satter Muneer A | Dir, 10% | P - Purchase | $4.01 | +130,000 | 11,132,277 | +1% | +$521,229 | |||||
2017-09-12 | PRGO | Perrigo Co Plc | Janish Ronald Craig | EVP, Global Op., Supply Chain | S - Sale | $88.71 | -261 | 5,972 | -4% | -$23,154 | ||||||
2017-09-12 | PRGO | Perrigo Co Plc | Needham Jeffrey | EVP, Pres CHC Americas | S - Sale | $89.49 | -3,595 | 9,718 | -27% | -$321,707 | ||||||
| M | 2017-09-12 | EBS | Emergent Biosolutions Inc. | El-Hibri Fuad | COB, 10% | S - Sale | $38.50 | -25,000 | 7,448,621 | 0% | -$962,500 | |||||
| A | 2017-06-29 | KDMN | Kadmon Holdings, Inc. | Goldentree Asset Management LP | 10% | S - Sale | $4.04 | -64,415 | 1,270,115 | -5% | -$260,546 | |||||
| D | 2017-09-13 | AVDL | Avadel Pharmaceuticals Plc | Thompson Phillandas T. | See Remarks | P - Purchase | $9.36 | +5,000 | 63,000 | +9% | +$46,800 | |||||
| D | 2017-09-12 | AVDL | Avadel Pharmaceuticals Plc | Stapleton Craig R | Dir | P - Purchase | $9.52 | +20,000 | 633,878 | +3% | +$190,360 | |||||
| D | 2017-09-12 | AVDL | Avadel Pharmaceuticals Plc | Divis Greg J | See Remarks | P - Purchase | $9.32 | +10,600 | 10,600 | New | +$98,760 | |||||
| D | 2017-09-12 | AVDL | Avadel Pharmaceuticals Plc | Anderson Michael S | CEO | P - Purchase | $9.79 | +4,000 | 229,750 | +2% | +$39,180 | |||||
| D | 2017-09-12 | CELG | Celgene Corp /de/ | Kaplan Gilla | Dir | S - Sale+OE | $141.56 | -9,250 | 76,301 | -11% | -$1,309,430 | |||||
2017-09-13 | VTL | Vital Therapies Inc | Bienaime Jean Jacques | Dir | P - Purchase | $4.00 | +10,000 | 65,119 | +18% | +$39,969 | ||||||
2017-09-14 | SBPH | Spring Bank Pharmaceuticals, Inc. | Driscoll Martin J | Pres, CEO | P - Purchase | $14.84 | +1,000 | 55,400 | +2% | +$14,840 | ||||||
| M | 2017-09-12 | ENDV | Endonovo Therapeutics, Inc. | Mann Michael Scott | Pres, 10% | P - Purchase | $0.03 | +70,000 | 23,451,189 | 0% | +$1,788 | |||||
| M | 2017-09-08 | ENDV | Endonovo Therapeutics, Inc. | Mann Michael Scott | Pres, 10% | P - Purchase | $0.03 | +89,000 | 23,381,189 | 0% | +$2,269 | |||||
2017-09-13 | AMAR | Amarillo Biosciences Inc | Chen Stephen T | Pres, CEO, COB, 10% | P - Purchase | $0.27 | +1,000 | 3,862,696 | 0% | +$272 | ||||||
2017-09-12 | PFE | Pfizer Inc | Susman Sally | EVP | S - Sale | $35.00 | -38,230 | 115,730 | -25% | -$1,338,050 | ||||||
2017-09-12 | JAZZ | Jazz Pharmaceuticals Plc | Cozadd Bruce C | COB, CEO | S - Sale | $153.52 | -1,000 | 277,664 | 0% | -$153,520 | ||||||
2017-09-11 | FGEN | Fibrogen Inc | Cotroneo Pat | VP, Finance, CFO | S - Sale | $49.45 | -2,851 | 157,405 | -2% | -$140,982 | ||||||
2017-09-11 | SCMP | Sucampo Pharmaceuticals, Inc. | Ueno Ryuji | 10% | S - Sale | $12.00 | -1,000,000 | 8,006,585 | -11% | -$12,000,000 | ||||||
2017-09-11 | SCMP | Sucampo Pharmaceuticals, Inc. | Kuno Sachiko | 10% | S - Sale | $12.00 | -1,000,000 | 7,137,344 | -12% | -$12,000,000 | ||||||
| DM | 2017-09-11 | MACK | Merrimack Pharmaceuticals Inc | Nielsen Ulrik B. | Dir | S - Sale+OE | $14.40 | -21,556 | 22,681 | -49% | -$310,408 | |||||
| D | 2017-09-11 | ALKS | Alkermes Plc. | Biberstein Kathryn L | EVP, CAO, CCO Alks Inc; Sec AL | S - Sale+OE | $51.29 | -13,566 | 150,889 | -8% | -$695,817 | |||||
| D | 2017-09-11 | AGIO | Agios Pharmaceuticals Inc | Bowden Christopher | Chief Medical Officer | S - Sale+OE | $65.00 | -6,000 | 881 | -87% | -$390,000 | |||||
2017-09-11 | AGIO | Agios Pharmaceuticals Inc | Biller Scott | Chief Scientific Officer | S - Sale | $65.00 | -15,000 | 16,734 | -47% | -$975,000 | ||||||
| D | 2017-09-11 | KPTI | Karyopharm Therapeutics Inc. | Mirza Mansoor Raza | Dir | S - Sale+OE | $11.00 | -118 | 0 | -100% | -$1,298 | |||||
2017-09-12 | RDUS | Radius Health, Inc. | Biotech Growth N V | 10% | P - Purchase | $35.42 | +50,000 | 5,348,799 | +1% | +$1,770,820 | ||||||
| DM | 2017-09-08 | PAHC | Phibro Animal Health Corp | Miller Larry Lee | COO | S - Sale+OE | $36.33 | -46,102 | 0 | -100% | -$1,674,693 | |||||
| DM | 2017-09-08 | PAHC | Phibro Animal Health Corp | Johnson Richard G | CFO | S - Sale+OE | $36.32 | -47,264 | 0 | -100% | -$1,716,456 | |||||
| D | 2017-09-11 | PAHC | Phibro Animal Health Corp | Carlson Gerald K | Dir | S - Sale+OE | $36.27 | -5,400 | 0 | -100% | -$195,858 | |||||
2017-09-12 | PTGX | Protagonist Therapeutics, Inc | Shames Richard S. | Chief Medical Officer | S - Sale | $14.31 | -3,687 | 0 | -100% | -$52,753 | ||||||
| D | 2017-09-11 | ABBV | Abbvie Inc. | Saleki-Gerhardt Azita | SVP, Operations | S - Sale+OE | $85.02 | -8,300 | 90,590 | -8% | -$705,655 | |||||
2017-09-08 | VTL | Vital Therapies Inc | Satter Muneer A | Dir, 10% | P - Purchase | $3.53 | +50,000 | 11,002,277 | 0% | +$176,615 | ||||||
2017-09-12 | LFVN | Lifevantage Corp | Jensen Darren Jay | CEO | P - Purchase | $4.22 | +2,400 | 149,358 | +2% | +$10,126 | ||||||
| M | 2017-09-08 | MYOK | Myokardia Inc | Third Rock Ventures Ii, L.P. | 10% | S - Sale | $41.30 | -221,250 | 135,303 | -62% | -$9,137,579 | |||||
2017-09-08 | MYOK | Myokardia Inc | Starr Kevin P | Dir, 10% | S - Sale | $41.01 | -201,250 | 7,564,156 | -3% | -$8,252,499 | ||||||
| D | 2017-09-08 | EBS | Emergent Biosolutions Inc. | Havey Adam | EVP, Business Operations | S - Sale+OE | $37.06 | -7,885 | 26,046 | -23% | -$292,243 | |||||
2017-09-07 | ENDV | Endonovo Therapeutics, Inc. | Mann Michael Scott | Pres, 10% | P - Purchase | $0.03 | +30,000 | 23,292,189 | 0% | +$803 | ||||||
| M | 2017-09-06 | ENDV | Endonovo Therapeutics, Inc. | Mann Michael Scott | Pres, 10% | P - Purchase | $0.03 | +132,000 | 23,262,189 | +1% | +$3,392 | |||||
| DM | 2017-09-07 | SUPN | Supernus Pharmaceuticals Inc | Patrick Gregory S | VP, CFO | S - Sale+OE | $47.60 | -50,000 | 30,716 | -62% | -$2,379,779 | |||||
| D | 2017-09-07 | SUPN | Supernus Pharmaceuticals Inc | Schwabe Stefan K.F. | EVP R, D | S - Sale+OE | $46.59 | -95,000 | 1,855 | -98% | -$4,425,575 | |||||
2017-09-08 | SUPN | Supernus Pharmaceuticals Inc | Bhatt Padmanabh P. | SVP of IP, CSO | S - Sale | $49.86 | -5,000 | 12,500 | -29% | -$249,303 | ||||||
2017-09-11 | ACRX | Acelrx Pharmaceuticals Inc | Asadorian Raffi | CFO | P - Purchase | $3.24 | +7,000 | 7,000 | New | +$22,705 | ||||||
| D | 2017-09-07 | AIMT | Aimmune Therapeutics, Inc. | Rozenman Mary M. | See Remarks | S - Sale+OE | $22.50 | -30,000 | 129 | -100% | -$675,000 | |||||
2017-09-07 | PRGO | Perrigo Co Plc | Kochan Sharon | EVP, GM International | S - Sale | $81.36 | -318 | 10,481 | -3% | -$25,874 |
Real-time CSV? Options? Alerts? Contact us!
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |